Related Experiment Videos
Theoretical and empirical arguments in relation to elective lymph node dissection for melanoma
M Piepkorn1, M A Weinstock, R L Barnhill
1Department of Medicine, University of Washington School of Medicine, Seattle, USA.
Archives of Dermatology
|August 1, 1997
Summary
For localized melanoma, the therapeutic benefit of elective lymph node dissection remains uncertain despite a century of research. Sentinel lymph node mapping offers valuable prognostic and staging information for high-risk patients.
Area of Science:
- Oncology
- Surgical Oncology
- Dermatology
Background:
- The therapeutic benefit of elective lymph node dissection for clinically localized melanoma remains debated.
- Nonrandomized studies are limited by case selection bias, hindering firm conclusions.
Purpose of the Study:
- To review historical and recent data on elective lymph node dissection for melanoma management.
- To contextualize the findings of the recent Intergroup Melanoma Surgical Program update.
Main Methods:
- Review of historical clinical inquiry and randomized trials.
- Analysis of data from nonrandomized studies and a recent National Cancer Institute-sponsored update.
Main Results:
- Early randomized trials in the 1970s showed no significant survival benefit from elective lymphadenectomy.
- A recent update suggests a small survival benefit in a specific subgroup, but this may be due to chance from subgroup comparisons.
Conclusions:
- The therapeutic benefit of elective lymphadenectomy for melanoma is still uncertain.
- Sentinel lymphatic mapping with selective lymphadenectomy provides crucial prognostic and staging data for adjuvant therapies and clinical trials.